{
    "clinical_study": {
        "@rank": "57289", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability of an oral Farnesyl\n      Protein Transferase\n\n      Inhibitor (SCH 66336) when given in combination with Gemcitabine and Cisplatin in patients\n      with advanced cancer."
        }, 
        "brief_title": "Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)", 
        "completion_date": {
            "#text": "July 2004", 
            "@type": "Actual"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced cancer for which there is no treatment available which would have a\n             reasonable chance of disease palliation or cure\n\n          -  Age greater than or equal to 18.\n\n          -  SWOG performance Status less than or equal to 2.\n\n          -  Meets protocol requirements for specified laboratory values.\n\n          -  Written informed consent and cooperation of patient.\n\n        Exclusion Criteria:\n\n          -  Prior treatment with an FPTI\n\n          -  Knowledge of intracranial metastases or carcinomatous meningitis.\n\n          -  Poor medical risks because of nonmalignant systemic disease or uncontrolled active\n             infection.\n\n          -  Medical conditions that would interfere with taking oral medications.\n\n          -  Significant uncontrolled diarrhea.\n\n          -  Chemotherapy, radiotherapy or major surgery within 4 weeks; full recovery from prior\n             treatment.\n\n          -  Concomitant use of CYP3A inhibitors/inducers per protocol.\n\n          -  Known HIV positivity or AIDS-related illness.\n\n          -  Pregnant or nursing women.\n\n          -  Men or women of childbearing potential who are not using an effective method of\n             contraception.\n\n          -  Concurrent chemotherapy, hormonal therapy, radiotherapy or immunotherapy.\n\n          -  QTc prolongation (>440 msecs) at baseline.\n\n          -  Patients with previous high-dose therapy requiring stem cell rescue or bone marrow\n             transplant, or irradiation to >30% of bone marrow-containing areas.\n\n          -  Patients that have received Mitomycin-C or nitrosoureas."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 28, 2002", 
        "id_info": {
            "nct_id": "NCT00040534", 
            "org_study_id": "P01499"
        }, 
        "intervention": {
            "intervention_name": "Farnesyl Protein Transferase Inhibitor", 
            "intervention_type": "Drug"
        }, 
        "keyword": "Advanced Cancer", 
        "lastchanged_date": "February 20, 2014", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2004", 
            "@type": "Actual"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040534"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "18058098", 
            "citation": "Chow LQ, Eckhardt SG, O'Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Sep;62(4):631-46. Epub 2007 Dec 6."
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }, 
    "geocoordinates": {}
}